SEC shines reg­u­la­to­ry spot­light on I-Mab, Sino­vac and oth­ers as more Chi­nese biotechs scram­ble to com­ply with new law

More Chi­nese biotech com­pa­nies are be­ing called out as the SEC re­leas­es a fresh batch of US-list­ed com­pa­nies that may, in a few years, be in breach of a new law and face the threat of delist­ing.

Ab­b­Vie-part­nered I-Mab, Covid-19 vac­cine mak­er Sino­vac, CAR-T de­vel­op­er Gra­cell Biotech­nolo­gies, Sanofi al­ly Ada­gene and lit­tle-known Burn­ing Rock Biotech have joined BeiGene, Hutchmed and Zai Lab in a group iden­ti­fied un­der the Hold­ing For­eign Com­pa­nies Ac­count­able Act.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER